Genetic enhancement of Ras-ERK pathway does not aggravate L-DOPA-induced dyskinesia in mice but prevents the decrease induced by lovastatin by Ruiz DeDiego, Irene et al.
1SCIENtIfIC REPORts |  (2018) 8:15381  | DOI:10.1038/s41598-018-33713-3
www.nature.com/scientificreports
Genetic enhancement of Ras-
ERK pathway does not aggravate 
L-DOPA-induced dyskinesia in mice 
but prevents the decrease induced 
by lovastatin
Irene Ruiz-DeDiego1,2, Stefania Fasano3, Oscar Solís  1,2, José-Rubén Garcia-Montes1,2, 
José Brea4,5, María I. Loza4,5, Riccardo Brambilla3 & Rosario Moratalla  1,2
Increasing evidence supports a close relationship between Ras-ERK1/2 activation in the striatum and 
L-DOPA-induced dyskinesia (LID). ERK1/2 activation by L-DOPA takes place through the crosstalk 
between D1R/AC/PKA/DARPP-32 pathway and NMDA/Ras pathway. Compelling genetic and 
pharmacological evidence indicates that Ras-ERK1/2 inhibition prevents LID onset and may even revert 
already established dyskinetic symptoms. However, it is currently unclear whether exacerbation of 
Ras-ERK1/2 activity in the striatum may further aggravate dyskinesia in experimental animal models. 
Here we took advantage of two genetic models in which Ras-ERK1/2 signaling is hyperactivated, the 
Nf1+/− mice, in which the Ras inhibitor neurofibromin is reduced, and the Ras-GRF1 overexpressing 
(Ras-GRF1 OE) transgenic mice in which a specific neuronal activator of Ras is enhanced. Nf1+/− and 
Ras-GRF1 OE mice were unilaterally lesioned with 6-OHDA and treated with an escalating L-DOPA 
dosing regimen. In addition, a subset of Nf1+/− hemi-parkinsonian animals was also co-treated with 
the Ras inhibitor lovastatin. Our results revealed that Nf1+/− and Ras-GRF1 OE mice displayed similar 
dyskinetic symptoms to their wild-type counterparts. This observation was confirmed by the lack of 
differences between mutant and wild-type mice in striatal molecular changes associated to LID (i.e., 
FosB, and pERK1/2 expression). Interestingly, attenuation of Ras activity with lovastatin does not 
weaken dyskinetic symptoms in Nf1+/− mice. Altogether, these data suggest that ERK1/2-signaling 
activation in dyskinetic animals is maximal and does not require further genetic enhancement in the 
upstream Ras pathway. However, our data also demonstrate that such a genetic enhancement may 
reduce the efficacy of anti-dyskinetic drugs like lovastatin.
Parkinson’s disease (PD) is the second most common neurodegenerative disorder after Alzheimer’s disease. This 
progressive, chronic, and age-related pathology is characterized by a dramatic depletion of dopamine in the stri-
atum following loss of dopaminergic neurons in the substantia nigra pars compacta. Despite extensive investi-
gation aimed at finding new therapeutic approaches, the dopamine precursor molecule L-DOPA remains the 
most effective and widely used non-invasive therapy for PD. However, in the vast majority of patients, chronic 
treatment and disease progression cause the appearance of abnormal involuntary movements known as dyski-
nesias. L-DOPA-induced dyskinesia (LID) interferes significantly with normal motor activity and persists unless 
L-DOPA dosages are reduced below therapeutic levels. Thus, controlling dyskinetic symptoms is one of the major 
challenges in PD therapy1,2.
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Extensive work indicates that extracellular signal-regulated kinase 1/2 (ERK1/2) activation in the stri-
atum plays a critical role in the emergence of LID1–12. This activation takes place by two interplaying cas-
cades: the D1R/cAMP/PKA/DARPP-32 pathway and the NMDA/Ras pathway. In the dopamine-depleted 
striatum, L-DOPA leads to D1R activation and stimulation of adenylyl cyclase through Gαolf protein13, 
increasing cAMP accumulation and activating PKA, modulating synaptic plasticity14,15. In turn, PKA phos-
phorylates DARPP-32 at Thr349,16–18, which in its phosphorylated state acts as a potent inhibitor of protein 
phosphatase-1 (PP1). The inhibition of PP-1 thereby controls many downstream effectors, including activation 
of mitogen-activated protein kinase (MEK, which phosphorylates ERK1/2) and inhibition of STEP (which 
dephosphorylates ERK1/2)19. Importantly, genetic deletion or pharmacological blockade of D1R prevents the 
supersensitive ERK1/2 response and LID4,20.
In addition to D1R-pathway, the ERK1/2 cascade can also be activated by the NMDA receptor via Ras21,22. In 
this pathway, lovastatin, a drug widely used to treat hyperlipidemia and able to reduce Ras activity by inhibiting 
its isoprenylation, significantly attenuates the phosphorylation of ERK1/2 and the development of LID23,24. In 
addition, genetic inactivation of the Ras-guanine nucleotide-releasing factor 1 (Ras-GRF1), a neuronal specific 
activator of Ras, attenuates dyskinesia in mice and non-human primates3,5.
The neurofibromatosis type 1 (Nf1) gene codes for neurofibromin, a cytoplasmic protein that functions as a 
GTPase-activating protein for Ras25,26. Neurofibromin inhibits Ras activity by catalyzing the conversion of Ras 
from its active GTP-bound (Ras-GTP) to its inactive GDP-bound form27,28. Reduced neurofibromin expression 
by Nf1 gene mutations is associated with increased Ras-ERK1/2 activation29,30 and, in the brain, with learning 
and memory deficits27,31–33. Interestingly, pharmacological inhibition of Ras activity with lovastatin ameliorates 
the observed behavioral abnormalities in mice and humans34–36. In the present work, we investigated the role of 
ERK1/2 over-activation in LID with two different approaches: a “direct” approach using Ras-GRF1 overexpress-
ing (Ras-GRF1 OE) transgenic mice, and an “indirect” intervention, favoring the maintenance of Ras in its active 
form by decreasing the neurofibromin levels using Nf1+/− transgenic animals.
Results
Basal locomotor activity and motor coordination are normal in Nf1+/− mutant mice. In order 
to rule out any baseline motor impairment in the mutant mice, we carried out spontaneous locomotor activity 
and rotarod tests prior to the 6-OHDA lesion. Since previous experiments from Fasano and colleagues37 demon-
strated that the increase of Ras-GRF1 expression in Ras-GRF1 OE mice does not affect locomotor activity and 
motor coordination in these animals, we focused on testing these behavioral performances in Nf1+/− mice. Nf1+/− 
and wild-type (WT) mice showed similar horizontal and vertical activity, as indicated by the number of beam 
breaks measured in a multi-cage activity meter system (Fig. 1A,B). Ambulatory activity measured as total distance 
traveled was also similar in both genotypes (Fig. 1C). Likewise, there were no statistically significant differences 
between genotypes in motor coordination (Fig. 1D), measured as the latency to fall from the rotarod. These 
results indicated that alterations in Nf1 gene expression do not modify spontaneous locomotor activity or motor 
coordination.
Nf1+/− mutant mice show high striatal Ras-GTP levels but reduced cAMP levels. Next, to 
confirm that Nf1+/− mice showed a higher activation of the Ras-ERK1/2 signaling pathway, we studied striatal 
Ras-GTP levels in naïve animals. As expected, we found that Nf1+/− mice displayed higher levels of Ras-GTP 
compared to WT mice (Fig. 1E and supplementary Fig. S1). We also examined whether the mutation in neu-
rofibromin could modulate the activity of Gαolf protein by testing cAMP levels in the striatum. Interestingly, we 
found a decrease in cAMP levels in Nf1+/− mutant mice relative to WT counterparts (Fig. 1F).
Heterozygous deletion of Nf1 has no effect on L-DOPA-induced dyskinesia or LID-associated 
changes in gene expression. To explore the role of Nf1 in dyskinesia, we studied the development of LID 
in hemiparkinsonian/6-OHDA-lesioned mice by scoring axial dystonia and forelimb and orofacial dyskinesias in 
Nf1+/− and their WT littermates. Since high L-DOPA doses can mask subtle differences between genotypes, we 
used an escalating dosing regimen in which L-DOPA was given i.p. daily for 9 days, with the daily dose increasing 
over the course of treatment (5, 10, and 20 mg/kg i.p., 3 consecutive days at each dose).
Daily scoring of AIMs (abnormal involuntary movements, i.e., axial dystonia, forelimb and orofacial dys-
kinesia) revealed a gradual development of dyskinesia in both genotypes, with AIMs scores increasing as the 
L-DOPA dose ascended. Interestingly, heterozygous Nf1 mutation had no effect on dyskinetic scores at any of 
the three L-DOPA doses: there were no significant differences in total dyskinetic scores between Nf1+/− and WT 
mice across the 9-day L-DOPA treatment (Fig. 2D). Both transgenic and WT mice showed great lateral deviation, 
twisted posture, contralateral forelimb dyskinesia, and jaw movements with tongue protrusion, with no statisti-
cally significant differences between genotypes for any of the three AIMs subtypes (Fig. 2A,C).
Correlating with these behavioral results, analysis of the dorsolateral striatum showed that L-DOPA-induced 
expression of FosB and pERK1/2 were similar in both genotypes (Fig. 3A), as well as pAcH3 expression (data 
not shown). The percentage of denervated striatum also demonstrated no different denervation between groups 
(Fig. 3B,B′).
Overexpression of Ras-GRF1 does not affect L-DOPA-induced dyskinesia. We next explored 
the effects of direct intervention in Ras signaling by using Ras-GRF1 overexpressing (Ras-GRF1 OE) mice37,38. 
Ras-GRF1 protein levels in these animals are threefold higher than in WT. Importantly, we previously shown that 
Ras-GRF1 OE mice are more sensitive to cocaine as measured by enhanced ERK1/2 activation in the striatum and 
increased behavioral responses37. Similarly to Nf1+/− mice, Ras-GRF1 OE animals showed dyskinetic symptoms 
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upon an escalating dose protocol comparable to WT controls (Fig. 4A). Accordingly, both the percentage of den-
ervated striatum and the striatal expression of pERK1/2 and FosB were indistinguishable between Ras-GRF1 OE 
and WT mice (Fig. 4B,C).
Figure 1. Heterozygous Nf1 gene mutation does not affect basal locomotor activity but increased striatal Ras-
GTP levels. (A) Horizontal and (B) vertical activity and (C) total distance traveled measured for 60 min in a 
multicage activity meter system. (D) Motor coordination measured in the rotarod at constant acceleration 
and expressed as latency to fall from the rotating rod. Striatal Ras-GTP levels determined by WB analysis are 
increased in Nf1+/− naïve mice (E) while cAMP levels are decreased compared to their WT counterparts (F). 
Uncropped blots are provided in Suplementary Fig. S1. ****p < 0.0001 vs WT. n = 7–12.
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Lovastatin attenuates L-DOPA-induced dyskinesia severity in WT but not in Nf1+/− mice. To 
assess the effect of pharmacological blockade of Ras on LID we used lovastatin, a Ras activity inhibitor. Mice 
were pretreated with lovastatin (20 mg/kg i.p.) or 0.9% saline for 3 days, as previously described23. Afterwards, 
for 10 consecutive days, mice received 20 mg/kg of L-DOPA 2.5 h after lovastatin or saline administration. The 
time course of AIMs expression following 20 mg/kg L-DOPA treatment was similar in Nf1+/− and WT mice 
(Fig. 5A). Dyskinesia was evident at 20 minutes, peaked between 40 and 60 minutes, declined significantly by 
100–120 minutes, and disappeared after 140–160 minutes for both genotypes. WT mice treated with both drugs 
exhibited significantly less dyskinesia than those treated with L-DOPA only. In contrast, lovastatin had no effect 
on the intensity of LID in Nf1+/− transgenic mice. This difference was reflected in cumulative AIMs scores over 
the entire 160-min observation period (Fig. 5B). Those scores were reduced by lovastatin in WT mice but not in 
Nf1+/−. Analysis of the individual AIMs over the entire 160-min observation revealed that the effect of lovastatin 
in WT mice was evident in all the dyskinetic sub-symptoms (Fig. 5C). Intriguingly, lovastatin did not modify 
frequency or intensity of any individual dyskinetic symptoms in the Nf1+/− mutant mice.
To exclude any possible interaction of Nf1 mutation on the antiparkinsonian properties of L-DOPA, we per-
formed the rotarod test before and after the L-DOPA treatment. In the absence of L-DOPA, parkinsonian animals 
of both WT and Nf1+/− genotypes showed similar latencies to fall from the rotating rod (Fig. 5D), while under 
chronic L-DOPA treatment both groups of mice showed an improved motor performance, indicating a similar 
therapeutic response to L-DOPA.
Figure 2. Heterozygous Nf1 gene mutation does not modify dyskinetic behaviour induced by L-DOPA. 
Temporal profile of (A) axial dystonia, (B) forelimb dyskinesia, (C) orofacial dyskinesia and (D) cumulated total 
score induced by an escalating L-DOPA dosing regimen administered in 9 consecutive days. No differences 
were found between Nf1+/− mice and their littermate controls. n = 5–9.
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Discussion
The major finding of this study is that the onset and expression of LID in Nf1+/− and in Ras-GRF1 OE mice are 
indistinguishable from WT. This indicates that a genetic enhancement of the Ras-ERK1/2 pathway does not result 
in either an exacerbated dyskinetic behavior or in the increase of the associated molecular markers (i.e. FosB, 
pERK1/2 and pAcH3 expression). Moreover, we demonstrate that pharmacological inhibition of Ras function 
with lovastatin decreases dyskinetic signs in WT mice, although is unable to reduce LID in the Nf1+/− mice.
Since previous works indicate that there is a correlation between Ras-ERK1/2 activity levels and intensity of 
dyskinetic symptoms1,2,6,8,39, we expected that Nf1+/− and Ras-GRF1 OE mice would exhibit more dyskinesia 
than WT animals. However, this increase in dyskinetic symptoms is not evident in our transgenic mice, nor is an 
increase in the molecular changes induced by L-DOPA.
As expected, Nf1+/− mice showed higher striatal Ras-GTP levels compared to their WT littermates, due to 
the heterozygous deletion of Nf1 gene. In heterozygosis, neurofibromin is less efficient at converting Ras-GTP 
to its inactive form Ras-GDP, leading to higher levels of Ras-GTP as depicted in Fig. 6. On the other hand, this 
increase in the Ras-ERK1/2 signaling pathway seems to be counterbalanced by a decrease in the Gαolf-cAMP 
pathway, indicated by the lower cAMP striatal levels we found in Nf1+/− mice. These results are in line with those 
found in both Nf1 patient-derived induced pluripotent stem cell-neural progenitor cells and mouse Nf1+/− hip-
pocampal neurons40. Thus, we speculate that dyskinetic Nf1+/− mice have the Ras-ERK1/2 pathway increased and 
the Gαolf-cAMP pathway decreased in the striatum, generating a net effect similar to that found in WT animals 
and is responsible for the same dyskinetic behavior displayed. Moreover, a similar scenario could be found in the 
Ras-GRF1 OE mice since these animals have also increased Ras activity similar to that of the Nf1+/− mice. Future 
experiments to examine striatal cAMP activity in these mice may corroborate this idea.
Despite these negative results, we found that decreasing Ras activity with lovastatin decreases LID in WT 
mice but not in Nf1+/− mice. Chronic co-treatment with lovastatin and L-DOPA effectively decreases dyskinetic 
symptoms in WT mice, consistent with previous work in hemiparkinsonian rats23. In our study, we demon-
strate that the lovastatin-induced Ras-signaling pathway inhibition significantly reduced all AIMs in WT mice. 
These results are in line with previous findings using Ras-GRF1 knockout mice5, which also showed a decrease in 
LID. Taken together, this indicates that a direct inhibition in the Ras-ERK1/2 pathway is enough to reduce LID 
symptoms, but not to abolish them, as occurs when the D1R pathway is altered by a genetic ablation of D1R4. 
NMDA receptor antagonists do not modify ERK1/2 phosphorylation induced by D1R agonists in the denervated 
Figure 3. Heterozygous Nf1 gene mutation does not alter molecular changes induced by L-DOPA. (A) High-
power photomicrographs of denervated striatum from WT and heterozygous Nf1 mice immunostained for 
FosB and pERK1/2. Histogram represents the quantification of FosB and pERK1/2 immunoreactive positive 
nuclei. (B) Bar graphs show the percentage of depletion of dopaminergic fibers measured in the striatum. No 
differences were found between Nf1+/− and WT mice. n = 5–9. Scale bars = 50 µm, 500 µm.
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striatum41. Thus, these data suggest that D1R plays a more important role than the NMDA receptor in the control 
of ERK cascade following chronic L-DOPA treatment. However, it is also important to consider that metabotropic 
glutamate receptor type 5 (mGluR5) modulates D1R signaling pathway via ERK1/2 activation in the denervated 
striatum42–44. For instance, local infusion of a mGluR5 antagonist into the denervated striatum in hemiparkinso-
nian rats reduced D1R-agonist induced ERK1/2 signaling42.
In contrast with that found in WT animals, chronic administration of lovastatin did not diminish LID in 
transgenic Nf1+/− mice, which have upregulated Ras function. Thus, lovastatin Ras-inhibition is not sufficient 
to reduce dyskinetic symptoms in these mice. These results are in line with previous findings which showed that 
Ras inhibitors can rescue only some phenotypes in Nf1-deficient cell lines45 and that lovastatin cannot correct the 
behavioral or the PET imaging deficits in mice46. More recently, Payne and colleagues47 performed the last and 
largest statin study in children with NF1 and concluded that lovastatin is not an effective treatment for cognitive 
or behavioral deficits in this population. At the signaling level, previous work in vitro with hippocampal neurons 
from Nf1+/− mice showed that continuous lovastatin exposure normalizes both the attenuated cAMP levels and 
increased Ras activity in these mutant cells40. Thus, lovastatin decreases LID in WT animals by decreasing Ras 
activity, while in Nf1+/− mice, although it decreases Ras activity, does not change LID, possibly because it may 
increase cAMP with a null net effect.
Finally, previous experiments demonstrated that the increased Ras-GRF1 expression in Ras-GRF1 OE mice 
does not affect locomotor activity and motor coordination37. Here we tested these behaviors in Nf1+/− mice and 
found that these animals are indistinguishable from their WT littermates in motor activity and motor coordina-
tion, in agreement with previous observations in the open field test33 and the water maze focusing on swimming 
Figure 4. Overexpression of Ras-GRF1 does not alter dyskinetic symptoms or the associated molecular 
markers induced by L-DOPA. (A) Temporal profile of axial, limb and orofacial AIMs induced by an escalating 
L-DOPA dosing regimen administered in 9 consecutive days. (B) Histograms show the percentage of 
striatal TH immunoreactive fibers depletion as a measure of dopaminergic denervation. (C) High-power 
photomicrographs of striatum from WT and Ras-GRF1 OE mice immunostained for FosB and pERK1/2. Bar 
graphs represent the quantification of FosB and pERK1/2 immunoreactive positive nuclei. No differences were 
found between transgenic Ras-GRF1 OE mice and their littermate controls. n = 10–12. Scale bar = 50 µm.
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speed and other motor skills33 (for review see48). Since spontaneous locomotor activity and motor coordination 
are normal in the Nf1+/− mice, results of dyskinesia experiments are not due to motor impairment, but rather to 
the modification of Nf1-related molecular pathways. Importantly, genetic modification in Nf1+/− mice does not 
alter the kinetic profile of L-DOPA, as all animals show similar duration of the L-DOPA response and display 
similar performance skills in the rotarod test, demonstrating that the antiparkinsonian efficacy of L-DOPA is 
preserved in all the animals.
In conclusion, it appears from the present study that a plateau in ERK1/2-signaling activation may already be 
achieved in response to denervation and L-DOPA treatment, therefore a genetic enhancement of the Ras path-
way does not exacerbate dyskinetic behavior. However, the lack of anti-dyskinetic effect in response to lovastatin 
observed in mice with abnormally high Ras activity may be of clinical significance since patients affected by such 
condition – RASopathies - do exist and may be tested in this respect in the near future.
Methods and Materials
Animals. Since the Nf1 null mouse is lethal35,49, we used heterozygous mice for the Nf1 gene (Nf1+/−)27 
obtained by heterozygous mating and genotyped by PCR. Their WT littermates were used as controls. These 
Nf1+/− mutant mice do not develop any abnormalities and are commonly used to study the role of neurofibro-
min. Ras-guanine nucleotide-releasing factor 1 overexpressing (Ras-GRF1 OE) mice, which exhibit a significant 
Figure 5. Chronic lovastatin treatment reduces AIMs scores in WT but not in heterozygous Nf1 mice. (A) Time 
profile of AIMs evaluated for 1 min every 20 min during 160 min on last day of L-DOPA treatment. (B) Sum 
of total AIMs score during all observation periods. (C) Sum of all AIM subscores (axial, limb and orofacial) 
evaluated during all observation periods. (D) Motor coordination assessed of hemiparkinsonian mice before 
L-DOPA treatment (after lesion) and on day 14, 24 h after L-DOPA administration (ON L-DOPA) to verify that 
genetic manipulation of Nf1 does not modify the therapeutic effect of L-DOPA. *p = 0.01, **p < 0.001 vs WT. 
#p < 0.001 vs after lesion situation. n = 4–8.
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increase in p140Ras−GRF1 protein (three folds to WT levels), were obtained as previously reported37,38. Mice were 
housed under a 12-h light/dark cycle with ad libitum access to food. All experiments were performed in male 
and female 3–6 month old mice. Experimental protocols were approved by the Cajal Institute Committee on 
Human and Animal Experimentation and CSIC Ethics Committee, and were in accordance with guidelines of the 
European Union Council Directive (86/609/European Economic Community).
6-OHDA lesion and drug treatment. Nf1+/− mice and their WT littermates were anesthetized with 2% 
v/v isofluorane and received unilateral stereotaxic injections (2 × 2 μl) of 6-OHDA-HBr (5 μg/μl, 20 mM, contain-
ing 0.02% ascorbic acid, Sigma-Aldrich, St. Louis, Missouri, USA) in the left striatum at the following coordinates 
(mm from bregma): AP = +0.65, L = −2 and V = −4 and −3.5, as previously described8,50. Ras-GRF1 OE mice 
and their WT littermates were lesioned by the administration of 1 μl of 6-OHDA-HBr in the right ascending 
medial forebrain bundle at the following coordinates: AP = −0.7, L = −1.2 and V = −4.7, as described5.
Establishment of L-DOPA-induced dyskinesia: escalating L-DOPA dosing regimen. After 3 weeks of recovery, a 
set of Nf1+/− and WT animals were treated daily for 9 consecutive days with benserazide hydrochloride (10 mg/
kg i.p., Sigma-Aldrich), followed 20 minutes later by administration of L-DOPA methyl ester (Sigma-Aldrich), 
using an escalating dosing regimen with each dose administered for 3 consecutive days (5, 10 and 20 mg/kg i.p.). 
Similarly, Ras-GRF1 OE mice and their WT littermates were treated for 9 consecutive days with an escalating 
L-DOPA dosing regimen (3, 6 and 12 mg/kg i.p.) plus benserazide. In all cases control animals were treated daily 
with saline.
A second group of hemiparkinsonian Nf1+/− mice was used to assess the effect of lovastatin on development 
of LID. Lovastatin (Mevinolin; Sigma-Aldrich), in the lactone form, was dissolved in ethanol and incubated at 
50 °C in 0.1 N NaOH for 2 hours for the conversion to the sodium salt. Volume was adjusted with water and pH 
Figure 6. Schematic diagram illustrating D1R and NMDAR signaling cascades in heterozygous Nf1 mice. 
In the striatum, dopamine activates D1R leading to cAMP formation and PKA activation that in turn leads 
to ERK1/2 phosphorylation. In addition, stimulation of NMDAR promotes Ras activation through Ras-
GRF1 which catalyzes the conversion of inactive Ras-GDP to active Ras-GTP. This process is counteracted by 
neurofibromin, which diminishes Ras activity. However, in heterozygosis (Nf1+/−) the balance between Ras-
GTP and Ras-GDP is displaced towards the active form, favoring ERK1/2 phosphorylation while cAMP levels 
are reduced.
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was adjusted to 7.5 with HCl23,51. 3-weeks after lesion, mice were pretreated with lovastatin (20 mg/kg i.p.) or 0.9% 
saline for 3 days. Afterwards, for 10 consecutive days, mice received 20 mg/kg of L-DOPA 2.5 h after lovastatin or 
saline administration.
Behavioral analysis. Locomotor activity and motor coordination. Horizontal and vertical activities, as well 
as total distance traveled, were recorded in mice as described52. Motor coordination was measured using the 
rotarod (Ugo Basile, Italy) following an accelerating protocol, with increasing speed from 4 to 40 rpm over a 
5 minute period as described53. Briefly, mice were tested in 6 consecutive trials 20 minutes apart. Motor coordi-
nation was tested before 6-OHDA lesion (naïve), 3 weeks after lesion (Parkinsonian state), and during L-DOPA 
treatment (dyskinetic state, ON L-DOPA) on day 14, 24 hours after the last L-DOPA injection to avoid overtrain-
ing and the peak dyskinesia50,54.
Dyskinetic score. L-DOPA-induced dyskinesia was evaluated using a 0–4 severity scale previously estab-
lished5,8,55,56. Mice were placed in separate glass cylinders and AIMs were assessed daily for 1 minute (monitoring 
period) every 20 minutes after L-DOPA over a period of 2 h, or on day 13 in the lovastatin experiment. The total 
AIMs score is the sum of individual scores for each AIM subtype.
Immunohistochemistry and image analysis. Animals were sacrificed 1 hour after the last L-DOPA 
injection and perfused and fixed with 4% paraformaldehyde. Brains were cut into 30-µm-thick coronal sections 
and immunohistochemistry studies were carried out according to published procedures57–59 with the following 
antibodies: anti-tyrosine-hydroxylase (TH) (1:1000, Millipore, Temecula, CA, USA, ref. AB152), FosB (1:7500, 
Santa Cruz Biotechnology, Santa Cruz, CA, USA, ref. sc-48), pERK1/2 (1:250; Cell Signaling Technology, ref. 
9101 L) and phospho-(Ser10)-acetyl-(Lys14)-histone-3 (pAcH3, 1:1500, Upstate, Cell Signaling Solutions, Lake 
Placid, NY, USA, ref. 07–081).
Quantification of FosB, pAcH3 and pERK1/2 immunoreactivity was carried out by nucleus count with the 
“cell counter” plug-in in NIH ImageJ software3,5,11. The number of immunolabelled nuclei was determined in 
5–9 animals per group, using 5 serial rostrocaudal sections per animal and 2 counting frames on the dorsolateral 
striatum per section (0.091 mm2 each frame). Images were digitized with a light microscope (Leica, Heidelberg, 
Germany) under 40x objective. Before counting, images were threshold at a standardized gray-scale level, empiri-
cally determined by 2 different observers to allow detection of stained nuclei from low to high intensity, with sup-
pression of very lightly stained nuclei. The data are presented as number of stained nuclei per mm2 (mean ± SEM).
Quantification of TH immunoreactivity fibers in the striatum was performed with the NIH ImageJ software 
as previously described13,60, analyzing 6–9 rostrocaudal striatal sections per animal. Briefly, 4x lens color images 
were converted into a gray scale and the area of staining (i.e., denervated area) was quantified as percentage of the 
total striatal area. Data are presented as the percentage of depletion of dopaminergic fibers.
cAMP and Ras-GTP assay. All assays were performed on dissected striatum, snap-frozen in liquid nitro-
gen. cAMP levels were quantitated from tissue homogenized in 0.1 M HCl, using a cAMP HTRF kit (CisBio) 
following manufacturer’s instructions.
Active Ras (Ras-GTP) was detected by Raf1-RBD immunoprecipitation using the RAS activation kit 
(Millipore). Briefly 500 µl of homogenized extract were incubated with Raf-1 RBD and agarose for 45 min at 4 °C. 
Then samples were centrifuged for 10 seconds at 14000 × g and agarose pellets were washed three times in the 
same conditions. Pellets were resuspended in 40 µL of 2X Laemli buffer supplemented with 2 mM DTT and boiled 
for 5 min at 100 °C. Samples were then processed for WB by following manufacturer’s instructions. Total Ras was 
also detected as loading control. Both cAMP and Ras-GTP levels were normalized to the levels observed in the 
striatum of the WT group.
Statistical analysis. Both the behavioral and immunolabeling quantification data of L-DOPA 
ascending-dose experiment were analyzed by one-way ANOVA. cAMP and Ras-GTP levels data were 
evaluated by unpaired t-test. Lovastatin experiment data were analyzed by two-way ANOVA followed by 
Student-Newman-Keuls post hoc test. Differences were considered statistically significant at p < 0.05.
Data Availability
The data that support the findings of this study are available from the corresponding author upon reasonable 
request.
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